StreetInsider.com News Articles

Form EFFECT ProQR Therapeutics N.V.

Thu, 16 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260716/26776053.html

Form EFFECT ProQR Therapeutics N.V.

Thu, 16 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260716/26776053.html

Form 424B5 ProQR Therapeutics N.V.

Wed, 15 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260715/26774517.html

Form 424B5 ProQR Therapeutics N.V.

Wed, 15 Jul 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260715/26774517.html

Form SCHEDULE 13G/A ProQR Therapeutics N.V. Filed by: Privium Fund Management B.V.

Wed, 15 Jul 2026 11:55:00 -0400

si-local-file:///var/storage/secattach/20260715/26772945.html

Form SCHEDULE 13G/A ProQR Therapeutics N.V. Filed by: Privium Fund Management B.V.

Wed, 15 Jul 2026 11:55:00 -0400

si-local-file:///var/storage/secattach/20260715/26772945.html

Form 4 ProQR Therapeutics N.V. For: Jul 09 Filed by: de Boer Daniel Anton

Mon, 13 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260713/26760083.html

Form 4 ProQR Therapeutics N.V. For: Jul 09 Filed by: de Boer Daniel Anton

Mon, 13 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260713/26760083.html

Form 4 ProQR Therapeutics N.V. For: Jul 07 Filed by: de Boer Daniel Anton

Wed, 08 Jul 2026 14:55:00 -0400

si-local-file:///var/storage/secattach/20260708/26747183.html

Form 4 ProQR Therapeutics N.V. For: Jul 07 Filed by: de Boer Daniel Anton

Wed, 08 Jul 2026 14:55:00 -0400

si-local-file:///var/storage/secattach/20260708/26747183.html

Form F-3 ProQR Therapeutics N.V.

Mon, 06 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260706/26735581.html

Form F-3 ProQR Therapeutics N.V.

Mon, 06 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260706/26735581.html

Form SCHEDULE 13D/A ProQR Therapeutics N.V. Filed by: VAN HERK INVESTMENTS B.V.

Tue, 30 Jun 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260630/26714923.html

Form SCHEDULE 13D/A ProQR Therapeutics N.V. Filed by: VAN HERK INVESTMENTS B.V.

Tue, 30 Jun 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260630/26714923.html

Form 4/A ProQR Therapeutics N.V. For: Jun 02 Filed by: Hinsch Gylvin Lykke

Tue, 30 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260630/26713457.html

Form 4/A ProQR Therapeutics N.V. For: Jun 02 Filed by: Hinsch Gylvin Lykke

Tue, 30 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260630/26713457.html

Form 4 ProQR Therapeutics N.V. For: Jun 26 Filed by: Filius Bart

Tue, 30 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260630/26713433.html

Form 4 ProQR Therapeutics N.V. For: Jun 26 Filed by: Filius Bart

Tue, 30 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260630/26713433.html

Form 424B5 ProQR Therapeutics N.V.

Fri, 26 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260626/26694461.html

Form 424B5 ProQR Therapeutics N.V.

Fri, 26 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260626/26694461.html

Form 6-K ProQR Therapeutics N.V. For: Jun 26

Fri, 26 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260626/26694462.html

Form 6-K ProQR Therapeutics N.V. For: Jun 26

Fri, 26 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260626/26694462.html

ProQR prices $50M share offering with Eli Lilly joining as buyer

Thu, 25 Jun 2026 06:35:14 -0400

ProQR Therapeutics N.V. (Nasdaq: PRQR) announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share, raising approximately $50.0 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses.

Concurrently, ProQR entered into a share purchase agreement with Eli Lilly and Company, an existing shareholder and strategic partner, in a separately negotiated private placement. Lilly agreed to purchase 5,100,780 ordinary shares at the same $1.81 offering price, generating approximately $9.2 million in additional gross proceeds. The transaction allows Lilly to maintain its pro rata beneficial ownership in ProQR. The private placement shares will

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

Thu, 25 Jun 2026 06:35:00 -0400

LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer^™ RNA editing technology platform, today announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares (the “Offering”) at an offering price of $1.81 per share (the “Offering Price”), for total gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR.

Concurrently with the Offering, ProQR has entered into a share purchase agreement with

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

Thu, 25 Jun 2026 06:35:00 -0400

Concurrently with the Offering, ProQR has entered into a share purchase agreement with